linjc16/ctgov huggingface dataset:
Functional Magnetic Resonance Imaging Study on the Role of Awareness in Visual Perception in Healthy Adult Subjects.

Study Overview
=================
Brief Summary
-----------------
The objective of the study concerns the investigation of the role of awareness in visual perception, highlighting the brain systems involved during non-processing Aware of stimuli belonging to different semantic categories. Specifically, the theoretical perspective of reference is that of the so-called grounded cognition, according to which the representation of the concepts of semantic knowledge is conveyed by information sensorimotor and affective, introspective and social states. The main objective is therefore to evaluate whether the meaning of the stimulus can be extracted in the absence of awareness, investigating the neural response in the brain regions known to be involved in the conscious processing of stimuli belonging to the semantic categories in question. To this end, two different experimental paradigms were implemented. A first paradigm aimed at investigating the unconscious representation of semantic knowledge in the context of language, therefore using visual stimuli in lexical mode (words). A second paradigm aimed at investigating the same phenomena in the field of visual perception of objects in space, using stimuli in iconic mode (images).

Official Title
-----------------
Functional Magnetic Resonance Imaging Study on the Role of Awareness in Visual Perception in Healthy Adult Subjects.

Conditions
-----------------
Magnetic Resonance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 20 and 65; Italian mother tongue. Exclusion Criteria: clinical evidence of significant psychiatric or systemic neurological pathologies.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnetic resonance imaging for 62 healthy volunteers for measure the role of consciousness in visual perception. | The role of consciousness in visual perception, highlighting the brain areas involved during the processing of stimuli belonging to different semantic categories. | 2 years |
Poul Gjessing Versus T Loops for Orthodontic Maxillary Canine Retraction

Study Overview
=================
Brief Summary
-----------------
Poul Gjessing versus T loops for orthodontic maxillary canine

Detailed Description
-----------------
Split mouth study one side using Poul Gjessing spring and other side using T loops

Official Title
-----------------
Evaluation of Poul Gjessing Versus T Loops for Orthodontic Maxillary Canine Retraction: A Randomized Clinical Study

Conditions
-----------------
Canine Retraction

Intervention / Treatment
-----------------
* Device: Poul Gjessing
* Device: T loops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Class I or II div 1, orthodontic patients, with moderate to severe crowding who are indicated for maxillary first premolar extraction. 2- All permanent teeth are erupted (3rd molars are not included). 3- Good oral and general health. 4- No previous orthodontic treatment. Exclusion Criteria: - 1- Orthodontic cases that could be treated with no indication for extraction therapy. 2- Orthodontic cases that are indicate for the extraction of any tooth other than maxillary first premolars. 3- Patients with systemic diseases that might interfere with the of orthodontic tooth movement.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Evaluation of Poul Gjessing spring for orthodontic maxillary canine retraction<br>20 Orthodontic patient treated by Poul Gjessing spring for canine retraction split mouth. | Device: Poul Gjessing<br>* maxillary canine retraction<br>|
| Active Comparator: Evaluation of T loop for orthodontic maxillary canine retraction<br>20 Orthodontic patient treated by T loop for canine retraction split mouth | Device: T loops<br>* T loops<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of canine retraction distance |  | six months |
Effectiveness and Safety of Probiotic in Regulating Chronic Constipation

Study Overview
=================
Brief Summary
-----------------
To evaluate the effectiveness and safety of the use of probiotics as food supplements in regulating the intestinal habit of subjects with chronic constipation, in comparison with placebo.

Official Title
-----------------
Efficacy and Safety of Probiotic BLa80 in Modulating Bowel Habits in Subjects With Chronic Constipation

Conditions
-----------------
Chronic Constipation

Intervention / Treatment
-----------------
* Dietary Supplement: Probiotic
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic constipation (duration more than 3 months with less than three bowel movements per week and/or Bristol Scale 1 and 2). Exclusion Criteria: Diabetic patients. Pregnant patients. Breastfeeding patients. Patients requiring antibiotic treatment. Patients requiring treatment with tricyclic antidepressants, antiepileptics, antihistamines, antiparkinsonians, antipsychotics, antispasmodics, verapamil, monoamine oxidase inhibitors, opiates, sympathomimetics, antacids (with aluminum and calcium), antidiarrheals and nonsteroidal anti-inflammatory drugs. Patients who change the type of diet during the study. Patients with allergy or intolerance to any of the ingredients in the formulation of the product under study. Subjects with a history of pharmacological, alcoholic, or other substance abuse, or other factors that limit their ability to cooperate during the study. Excessive alcohol consumption (>3 glasses of wine or beer/day). Subjects whose condition does not make them eligible for the study, according to the researcher.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Probiotic group<br>2B CFU/capsule/day BLa80, before meals； Storage: Store in a cool, dry place without sun exposure. | Dietary Supplement: Probiotic<br>* The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).<br>|
| Placebo Comparator: placebo<br>Maltodextrin, one capsule/day, before meals； Storage: Store in a cool, dry place without exposure to the sun. | Dietary Supplement: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in fecal state | use Bristol Scale to record the type of fecal state | 84 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Probiotics；Chronic constipation
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

Study Overview
=================
Brief Summary
-----------------
This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months

Detailed Description
-----------------
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer.

Official Title
-----------------
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

Conditions
-----------------
Diabetic Foot Ulcer

Intervention / Treatment
-----------------
* Biological: ALLO-ASC-DFU
* Procedure: Vehicle sheet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who are treated with ALLO-ASC-DFU sheet or Vehicle sheet in phase 3 clinical trial of ALLO-ASC-DFU-302. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements. Exclusion Criteria: 1. Subjects who are considered not suitable for the study by the principal investigator.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ALLO-ASC-DFU<br>Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-302 | Biological: ALLO-ASC-DFU<br>* Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.<br>|
| Vehicle sheet<br>Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-302 | Procedure: Vehicle sheet<br>* Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of systemic tolerance through incidence of abnormal laboratory test results |  | Up to 9 months | 
| Evaluation of incidence of clinically significant change in physical examination and vital signs |  | Up to 18 months | 
| Evaluation of localized tolerance through incidence of clinically significant change about treatment area |  | Up to 24 months | 
| Evaluation of incidence of adverse events |  | Up to 24 months |
Preoperative BNP and MINS in AAA Open Repair

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to investigate whether preoperative B-type natriuretic peptides serves as an independent predictor of myocardial injury after non-cardiac surgery (MINS) in abdominal aortic aneurysm open repair.

Detailed Description
-----------------
The incidence of MINS was compared between the lower BNP and higher BNP groups, and a stepwise logistic regression analysis was performed to evaluate the predictors for MINS.

Official Title
-----------------
Prognostic Impact of Preoperative B-type Natriuretic Peptide for Predicting Myocardial Injury After Non-cardiac Surgery in Patients Who Underwent Open Repair for Abdominal Aortic Aneurysm: a Retrospective Study

Conditions
-----------------
Myocardial Injury After Non-cardiac Surgery

Intervention / Treatment
-----------------
* Diagnostic Test: preoperative BNP value


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent open repair with AAA from September 2010 to October 2021 Exclusion Criteria: Ruptured AAA Traumatic aortic injury Absence of troponin-T value within 30 days of surgery Diagnosis of elevation of troponin-T due to non-ischemic cause (ex: sepsis, pulmonary embolism, atrial fibrillation, cardioversion, etc.) Insufficient medical records

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lower BNP<br>preoperative Lower BNP | Diagnostic Test: preoperative BNP value<br>* preoperative BNP value<br>|
| Higher BNP<br>preoperative higher BNP | Diagnostic Test: preoperative BNP value<br>* preoperative BNP value<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MINS | MINS is defined as an elevated Troponin-T within 30 days of surgery. The patients were divided into two groups based on their preoperative BNP levels, and the incidence of MINS was compared between the two groups. | 30 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AAA, MINS, BNP
PK and PD Study of NPI-001 and Cysteamine Bitartrate

Study Overview
=================
Brief Summary
-----------------
Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.

Detailed Description
-----------------
This study will examine the safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients, aged ≥ 10 years. The ability of NPI-001 to reduce white blood cell (WBC) cystine will be assessed and compared with cysteamine.

Official Title
-----------------
A Phase 1/2 Pharmacokinetic and Pharmacodynamic Study of NPI-001 Oral Solution Compared to Cysteamine Bitartrate in Cystinosis Patients

Conditions
-----------------
Cystinosis

Intervention / Treatment
-----------------
* Drug: Cysteamine Bitartrate
* Drug: N-Acetylcysteine Amide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females, any race, ≥ 10 years of age. Diagnosis of nephropathic cystinosis and able to cease cysteamine therapy for 2 days. Females will be nonpregnant and nonlactating, and females of childbearing potential and males will agree to use contraception as detailed in the protocol. Able to comprehend and willing to sign an informed consent /assent form and to abide by the study restrictions (travel as necessary, clinical phase 1 unit or similar for up to 3 days). Exclusion Criteria: Have undergone kidney transplantation. Are receiving dialysis treatment. History of significant hypersensitivity to NAC or any ingredient of NPI-001 oral solution. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the 30 days prior to Day 1. Inability to provide blood samples, including difficulty with venous access. Subjects who, in the opinion of the Investigator and/or Sponsor (or designee), should not participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: cysteamine<br>Single dose, tablets in current treatment dose | Drug: Cysteamine Bitartrate<br>* Single dose, tablets at current therapeutic dose<br>* Other names: Cystagon;|
| Experimental: NPI-001<br>Single dose, NPI-001 (N-acetylcysteine amide) oral solution at molar equivalent of current cysteamine dose. | Drug: N-Acetylcysteine Amide<br>* Single dose, oral solution<br>* Other names: NPI-001;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of Cystine Levels Over Time | White Blood Cell cystine concentration over 6 hours | 1 day |
Low Level Lazer Therapy Effect on Vertebral Artery Blood Flow in Elderly With Cervical Disc Degeneration

Study Overview
=================
Brief Summary
-----------------
This study will include 60 elderly patients with cervical disc degeneration, from both gender who are aged from 60 - 75 years old.

Detailed Description
-----------------
The 60 patients will divided into two groups, with 30 patients in each group. group(A): will receive low level lazer and exercises for three times per week for 12 weeks. Group (B): will receive only exercises. Resistivity index of both right and left vertebral arteries will be measured before and after the 12 weeks.

Official Title
-----------------
Low Level Lazer Therapy Effect on Vertebral Artery Blood Flow in Elderly With Cervical Disc Degeneration

Conditions
-----------------
Disc Degeneration

Intervention / Treatment
-----------------
* Radiation: Low level Lazer therapy
* Other: Routine exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elderly patients with age range between 60 and 75 years old. with cervical disc degeneration. Exclusion Criteria: patients with uncontrolled hypertension. Patients with uncontrolled diabetes mellitus. Patients with severe cardiac or chest diseases.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Two groups Group (A) and group(B)
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lazer group<br>30 patients will receive low level lazer therapy 3 times per week for 12 weeks. | Radiation: Low level Lazer therapy<br>* 30 patients will receive low level lazer therapy 3 times a week for 12 weeks.<br>Other: Routine exercises<br>* 30 patients will receive only routine exercises 3 times a week for 12 weeks.<br>|
| Other: Control group<br>30 patients will receive only exercises. | Other: Routine exercises<br>* 30 patients will receive only routine exercises 3 times a week for 12 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resistivity index of both right and left vertebral arteries | Resistivity index of both right and left vertebral arteries will be measured before and after the 12 weeks. | 12 weeks |
Minimally Invasive Robot-assisted and Laparoscopic Distal Pancreatectomy in a Pan-European Registry

Study Overview
=================
Brief Summary
-----------------
A planned analysis of outcomes among consecutive patients after MIDP from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were intraoperative events, major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Detailed Description
-----------------
The European registry for Minimally Invasive Pancreatic Surgery (E-MIPS) is an E-AHPBA endorsed registry with the aim to monitor and safeguard the introduction of MIPS in Europe. International multicenter audit-based studies focusing on outcomes of minimally invasive distal pancreatectomy (MIDP) are lacking. A planned analysis of outcomes among consecutive patients after MIDP from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were intraoperative events, major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Official Title
-----------------
Minimally Invasive Robot-assisted and Laparoscopic Distal Pancreatectomy in a Pan-European Registry

Conditions
-----------------
Pancreas Disease

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Data from all patients who underwent laparoscopic or robotic distal pancreatecromy between January 1st 2019 and December 31st 2021 were included Exclusion Criteria: Other pancreatic procedures Hybrid approaches (reconstruction phase open) Procedures with insufficient baseline data / missing primary outcome data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative events | Major bleeding or change in operation | 30 days | 
| 30-day/in-hospital mortality. | Dead in hospital or within 30 days | 30 days |
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

Study Overview
=================
Brief Summary
-----------------
Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several other minor variants within the group of SCDs also, albeit not as common as the varieties mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is the most common form of SCD

Official Title
-----------------
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

Conditions
-----------------
Sickle Cell Disease

Intervention / Treatment
-----------------
* Diagnostic Test: urinary endothelin 1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients fulfilling all the following criteria will be included: Patients with sickle cell disease in the age range of 1-18years. Exclusion Criteria: Patients diagnosed to have coexistent renal disease before the study

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: urinary endothelin 1|assesment of endothelin 1 in urinary sample|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| renal affection in sickle cell patients | assessment of urinary endothelin 1 as a marker of renal impairment in sickle cell patients | 1 year |